Get the Stockscreener App
9.97
3.53%
0.34
After Hours:
9.98
0.010
+0.10%
Arcturus Therapeutics Holdings Inc stock is traded at $9.97, with a volume of 927.80K.
It is up +3.53% in the last 24 hours and down -45.90% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
See More
Previous Close:
$9.63
Open:
$9.81
24h Volume:
927.80K
Relative Volume:
0.80
Market Cap:
$270.73M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-8.5948
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
-11.14%
1M Performance:
-45.90%
6M Performance:
-22.17%
1Y Performance:
-43.77%
1-Day Range:
$9.6535
$10.04
1-Week Range:
$9.36
$11.47
52-Week Range:
$8.04
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
9.97 | 261.50M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-23-25 | Downgrade | Citigroup | Buy → Neutral |
| Oct-22-25 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
How to forecast Arcturus Therapeutics Holdings Inc. trends using time seriesQuarterly Growth Report & Accurate Intraday Trading Signals - newser.com
Real time scanner hits for Arcturus Therapeutics Holdings Inc. explainedQuarterly Risk Review & Expert Verified Movement Alerts - newser.com
Can momentum traders help lift Arcturus Therapeutics Holdings Inc.2025 Investor Takeaways & High Accuracy Swing Entry Alerts - newser.com
How Arcturus Therapeutics Holdings Inc. stock valuations compare to rivalsPortfolio Growth Summary & Real-Time Market Trend Scan - newser.com
Published on: 2025-11-01 04:30:36 - newser.com
Is Arcturus Therapeutics Holdings Inc. stock attractive for income investorsJuly 2025 Selloffs & Safe Entry Momentum Tips - newser.com
Is Arcturus Therapeutics Holdings Inc. stock ready for a breakoutTrade Volume Report & High Conviction Trade Alerts - newser.com
Sumitomo Mitsui Trust Group, Inc. Expands Stake in Arcturus Therapeutics Holdings Inc. - GuruFocus
High Growth Tech Stocks In US With Promising Potential - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arcturus Therapeutics Holdings Inc. (ARCT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2025-10-31 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arcturus Therapeutics Holdings Inc. (ARCT) and Encourages Investors to Learn More About the Investigation | NDAQ:ARCT | Press Release - Stockhouse
Advanced analytics toolkit walkthrough for Arcturus Therapeutics Holdings Inc.2025 Top Decliners & Fast Gain Swing Trade Alerts - newser.com
Can Arcturus Therapeutics Holdings Inc. stock beat market expectations this quarterRate Hike & Verified Momentum Stock Watchlist - newser.com
How currency fluctuations impact Arcturus Therapeutics Holdings Inc. stockPortfolio Update Report & Proven Capital Preservation Methods - newser.com
What technical models suggest about Arcturus Therapeutics Holdings Inc.’s comebackJuly 2025 EndofMonth & Weekly Momentum Stock Picks - newser.com
How Arcturus Therapeutics Holdings Inc. stock compares to market leaders2025 Momentum Check & Free Expert Verified Stock Movement Alerts - newser.com
What candlestick patterns are forming on Arcturus Therapeutics Holdings Inc.2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com
Is Arcturus Therapeutics Holdings Inc. stock cheap at current valuationEarnings Trend Report & Weekly Return Optimization Alerts - newser.com
Arcturus Therapeutics Holdings (ARCT) Price Target Decreased by 30.87% to 45.67 - MSN
Arcturus Therapeutics Holdings Inc. (ARCT) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Arcturus Therapeutics Holdings Inc. (ARCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Published on: 2025-10-30 03:05:20 - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arcturus Therapeutics Holdings Inc. (ARCT) And Encourages Investors to Connect - ACCESS Newswire
Arcturus Therapeutics Holdings Inc. $ARCT Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
What MACD signals say about Arcturus Therapeutics Holdings Inc.Earnings Summary Report & Community Trade Idea Sharing - newser.com
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 - BioSpace
Arcturus Therapeutics Holdings Inc (NQ: ARCT - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc.ARCT - PR Newswire
Why Arcturus Therapeutics Holdings Inc. stock attracts high net worth investorsIPO Watch & Technical Analysis for Trade Confirmation - Fundação Cultural do Pará
The Market Doesn't Like What It Sees From Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Revenues Yet As Shares Tumble 52% - simplywall.st
Will Arcturus Therapeutics Holdings Inc. stock gain from lower inflationMarket Risk Summary & Free Safe Capital Growth Stock Tips - Fundação Cultural do Pará
Published on: 2025-10-27 17:17:45 - Fundação Cultural do Pará
Market Recap: How Arcturus Therapeutics Holdings Inc. stock valuations compare to rivalsPortfolio Gains Report & Weekly High Return Stock Forecasts - Fundação Cultural do Pará
Arcturus Therapeutics2025 Funding Rounds & List of Investors - Tracxn
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):